---
title: Timolol Eye Drops in the Treatment of Acute Migraine Headache
nct_id: NCT02630719
overall_status: TERMINATED
phase: NA
sponsor: University of Missouri, Kansas City
study_type: INTERVENTIONAL
primary_condition: Migraine
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02630719.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02630719"
ct_last_update_post_date: 2019-05-15
last_seen_at: "2026-05-12T07:16:46.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Timolol Eye Drops in the Treatment of Acute Migraine Headache

**NCT ID:** [NCT02630719](https://clinicaltrials.gov/study/NCT02630719)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Unable to enroll sufficient participants
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 10
- **Lead Sponsor:** University of Missouri, Kansas City
- **Collaborators:** Truman Medical Center
- **Conditions:** Migraine
- **Start Date:** 2016-01
- **Completion Date:** 2017-08-01
- **CT.gov Last Update:** 2019-05-15

## Brief Summary

The goal of this study is to determine whether timolol eye drops are effective in alleviating acute migraine headaches. Subjects will be randomized to receive either timolol eye drops or placebo (tears) to use as a migraine abortive medication.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Diagnosis of migraine headache

Exclusion Criteria

* Non-migraine headache
* Use of systemic beta-blocker
* Medical history of hypotension, bradycardia, syncope or other significant cardiovascular disease
* Medical history of difficulty breathing, asthma or chronic obstructive pulmonary disease or other pulmonary disease
* Medical history of glaucoma, ocular hypertension or hypotony, punctual stenosis, current use of other ophthalmic medications
* Previous adverse reaction to timolol or other beta-blockers
* Inability to self-administer eye drop due to physical or cognitive disorders
* Currently pregnant or breastfeeding
* Pregnant in the past year
* Non-english speaker
```

## Arms

- **Timolol eye drops** (ACTIVE_COMPARATOR) — All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
- **Artificial tears** (PLACEBO_COMPARATOR) — All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.

## Interventions

- **Timolol eye drops** (DRUG) — eye drops
- **Artificial tears** (DRUG) — Placebo drop

## Primary Outcomes

- **Timolol Eye Drops in the Treatment of Acute Migraine Headache** _(time frame: 4 months)_ — Percent of migraine attacks at 0 or 1 on the 4-point Rating Scale recommended by the International Headache Society:

0: no headache

1. mild headache
2. moderate headaches
3. severe headache

## Locations (1)

- Truman Medical Center, Kansas City, Missouri, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.truman medical center|kansas city|missouri|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02630719.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02630719*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*